NanoViricides' President Chosen As Special Lecturer at Nanotechnology Conference - Biomedical Applications Attended by Leading Government and Industry Scientists: Company On Target With Its Planned Studies Of H1N1, H5N1, And Rabies, To Be Independently Monitored, Scheduled For The First Quarter 2007

Business Wire - December 11, 2006

WEST HAVEN, Conn. -- NanoViricides, Inc., (Pink Sheets: NNVC) Dr. Anil Diwan, Company President and Chairman, was selected to speak at "Advances in Nanotechnology Conference - Biomedical Applications, 2006" held at the Moffitt Cancer Center in Tampa, FL, on Dec. 8th. He outlined the significant advantages of the nanoviricides(tm) approach, and the underlying nanomicelle(tm) polymeric micelle technologies, over currently existing technologies.

Dr. Diwan also made it clear that only the nanoviricides technology offers a solution to potential pandemic-causing attacks by novel pathogens, whether they occur as a result of bioterrorism or natural events. This is of major interest to Biodefense professionals. In addition he explained how the Company's technologies can be of significant assistance to the bio-emergency preparedness efforts that are occurring world-wide.

"The leadership position of NanoViricides in the field of NanoMedicine is well recognized," said Eugene Seymour, MD, CEO, about this presentation.

Previously, Dr. Seymour presented the Company's work at the 3rd International Bird Flu Conference in Geneva, Switzerland on November 15th. He stressed the fact to the International Health audience assembled at the Conference that the Company's scientists were working as fast as possible on both avian and seasonal influenza drug developments, "now that it is clear that the nanoviricides are the most efficacious drugs against all influenzas."

NanoViricides also announced that it is on target with its planned studies of H1N1 (common influenza), H5N1 (bird flu), and rabies scheduled for the first quarter 2007, as explained in the Company's filed SEC Form 10SB. The success of these animal studies, to be independently monitored by Vietnamese government scientists, would be expected to result in the creation of drugs with "blockbuster" potential. However even more important to our shareholders and the general public, this will further validate the nanoviricides(tm) technology and hasten the development of drugs by NanoViricides with even larger market sizes such as Hepatitis C (HCV) and HIV.

About NanoViricides - http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

CONTACT: NanoViricides, Inc.

Leo Ehrlich, 917-853-6440

leo@nanoviricides.com

SOURCE: NanoViricides, Inc.
061211
BW061209

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .